RMC-6291
CAS No. 2641998-63-0
RMC-6291( —— )
Catalog No. M36627 CAS No. 2641998-63-0
RMC-6291 is an orally active, covalent inhibitor of KRAS G12C (ON) that forms a tri-complex within tumor cells between KRAS G12C (ON) and cyclophilin A (CypA), thereby preventing KRAS G12C (ON) from signaling via steric blockade of RAS effector binding and eliciting deep and durable suppression of RAS pathway activity in KRAS G12C tumor models .
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 246 | Get Quote |
|
| 5MG | 372 | Get Quote |
|
| 10MG | 635 | Get Quote |
|
| 25MG | 1086 | Get Quote |
|
| 50MG | 1822 | Get Quote |
|
| 100MG | 2907 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameRMC-6291
-
NoteResearch use only, not for human use.
-
Brief DescriptionRMC-6291 is an orally active, covalent inhibitor of KRAS G12C (ON) that forms a tri-complex within tumor cells between KRAS G12C (ON) and cyclophilin A (CypA), thereby preventing KRAS G12C (ON) from signaling via steric blockade of RAS effector binding and eliciting deep and durable suppression of RAS pathway activity in KRAS G12C tumor models .
-
DescriptionRMC-6291 is an orally active and covalent inhibitor of KRASG12C(ON). RMC-6291 forms a tri-complex within tumor cells between KRASG12C(ON) and cyclophilin A (CypA). Thus, RMC-6291 prevents KRASG12C(ON) from signaling via steric blockade of RAS effector binding. RMC-6291 elicits deep and durable suppression on RAS pathway activity in KRASG12C tumor models.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorKras
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2641998-63-0
-
Formula Weight1012.26
-
Molecular FormulaC55H78FN9O8
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (98.79 mM; Ultrasonic )
-
SMILESO=C(C#CC(N(C)C)(C)C)N1CCC(F)(C(=O)N(C)C(C(=O)NC2C(=O)N3NC(C(=O)OCC(C)(C)CC=4C5=CC(=CC=C5N(C4C=6C=CC=NC6C(OC)C)CC)N7CCOC(C7)C2)CCC3)C(C)C)CC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Nichols R J, et al. RMC-6291, a next-generation tri-complex KRASG12C (ON) inhibitor, outperforms KRASG12C (OFF) inhibitors in preclinical models of KRASG12C cancers[J]. Cancer Research, 2022, 82(12_Supplement): 3595-3595.
molnova catalog
related products
-
Smcy HY Peptide 738-...
Smcy HY Peptide (738-746) is a H2-Db-restricted peptide corresponding to amino acids 738-746 of Smcy protein.
-
MARCKS Peptide(151-1...
Myristoylated Alanine-Rich C Kinase Substrate peptide (151-175) is a high affinity Protein Kinase C substrate.
-
16alpha-Hydroxypredn...
16alpha-Hydroxyprednisolone is a stereoselective metabolite of the 22(R) epimer of the glucocorticoid budesonide.
Cart
sales@molnova.com